INmune Bio (NASDAQ: INMB) is a diversified
clinical-stage immunology company focused on developing treatments that harness
the patient’s innate immune system to combat disease. An article further
discussing the company reads, “Drug candidates INKmune and INB03 may be used to
treat cancer while XPro1595 targets neuroinflammation as a cause of Alzheimer’s
disease. INmune Bio’s product platforms utilize a precision therapy approach to
promote the body’s innate immune response to treat unsolved problems in medicine.
. . . INmune Bio is the first biotechnology company to close an initial public
offering (“IPO”) in 2019 and commence trading on The Nasdaq Capital Market. The
company also received a ‘Part the Cloud’ award from the Alzheimer’s Association
in 2018 which included a $1 million grant to advance INmune Bio’s XPro1595 drug
candidate.”
To view the full article, visit http://ibn.fm/b7EFw
About INmune Bio Inc.
INmune Bio Inc. is a publicly traded (NASDAQ: INMB)
clinical-stage biotechnology company developing therapies targeting the innate
immune system to fight disease. INmune Bio is developing three product
platforms: two products that reengineer the patient’s innate immune system’s
response to cancer and one product to treat neuroinflammation that is currently
focused on Alzheimer’s disease. INKmune is a natural killer (“NK”) cell
therapeutic that primes the patient’s NK cells to attack minimal residual
disease, the remaining cancer cells that are difficult to detect, which often
cause relapse. INB03 inhibits myeloid derived suppressor cells (“MDSC”), which
often cause resistance to immunotherapy, such as anti-PD-1 checkpoint
inhibitors. XPro1595 targets neuroinflammation, which causes microglial
activation and neuronal cell death. INmune Bio’s product platforms utilize a
precision medicine approach for the treatment of a wide variety of hematologic
malignancies, solid tumors and chronic inflammation. To learn more, please
visit www.INmuneBio.com.
NOTE TO INVESTORS: The latest news and updates
relating to INMB are available in the company’s newsroom at http://ibn.fm/INMB
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to established
industry leaders, gaining valuable experience and the expertise necessary to
determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
